Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis.
about
Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical Outcomes and Biologic ...... ans with Rheumatoid Arthritis.
@en
Clinical Outcomes and Biologic ...... ans with Rheumatoid Arthritis.
@nl
type
label
Clinical Outcomes and Biologic ...... ans with Rheumatoid Arthritis.
@en
Clinical Outcomes and Biologic ...... ans with Rheumatoid Arthritis.
@nl
prefLabel
Clinical Outcomes and Biologic ...... ans with Rheumatoid Arthritis.
@en
Clinical Outcomes and Biologic ...... ans with Rheumatoid Arthritis.
@nl
P2093
P2860
P1433
P1476
Clinical Outcomes and Biologic ...... rans with Rheumatoid Arthritis
@en
P2093
Andreas Reimold
Candace L Haroldsen
David H Collier
David J Harrison
George J Joseph
Grant W Cannon
Jeffrey R Curtis
Kaleb Michaud
Liron Caplan
Scott L DuVall
P2860
P2888
P304
P356
10.1007/S12325-016-0371-0
P407
P577
2016-06-28T00:00:00Z